AKTX PRESS-RELEASE SEC Filing Analysis

Latest settled — T+5d

AKTX ▼ -32.04% at T+5d

NEUTRAL call ✗ call lost -32.04% · α vs SPY -31.99% · entry $22.05 → $14.99

Next anchor: T+20d in 16d

Last close $15.44 (close Jun 8) · -29.95% from $22.05 entry

Entry anchored
May 28, 08:08 AM ET
via Databento tick

T+1d

-25.49%

call -25.49% · α -25.73%

$16.43

settled 12d ago

T+5d

-32.04%

call -32.04% · α -31.99%

$14.99

settled 6d ago

T+20d

—

call — · α —

—

in 16d

T+60d

—

call — · α —

—

in 2mo

Price Chart

Loading chart...

Executive Summary

Akari Therapeutics announced CEO participation in a Virtual Investor interview discussing its first ASCO abstract acceptance, highlighting preclinical data showing synergy between its PH1 spliceosome-modulating ADC platform and a KRAS inhibitor in pancreatic cancer models. The company targets a Phase 1 first-in-human trial start by mid-2027, but no new financial data or regulatory milestones were disclosed.

Actionable Insight

The ASCO abstract acceptance and preclinical synergy data are incremental positive signals for the platform, but the company remains pre-revenue with no near-term catalyst until the Phase 1 trial start (mid-2027). Monitor for further preclinical data releases and any financing updates given the $18M market cap.

Key Facts

First ASCO abstract acceptance for Akari, presenting preclinical data on AKTX-101 and PH1 payload platform.
Preclinical data demonstrated combination synergy between Akari's ADC platform and a KRAS inhibitor in KRAS-mutated pancreatic cancer models.
Company targets initiation of Phase 1 first-in-human clinical trial by mid-2027.
No new financial data, revenue, or earnings disclosed in the press release.
AKTX-101 targets Trop2 receptor; AKTX-102 targets CEACAM5, both using PH1 spliceosome-modulating payload.

Financial Impact

No financial figures disclosed; pre-revenue clinical-stage biotech with $18M market cap.

Risk Factors

No revenue or near-term commercial product; requires additional capital to fund operations and clinical trials.
Phase 1 trial start is targeted for mid-2027, with significant execution risk and potential delays.
Preclinical data may not translate to clinical efficacy; KRAS-driven cancers remain difficult to treat.
Small market cap ($18M) implies high volatility and limited liquidity.

Market Snapshot

Exchange

Nasdaq

Sector

Pharmaceutical Preparations

Analyst Consensus

80% bullish (10 analysts)

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

Document	Accession Number
PRESS-RELEASE Data (Synthetic)	press-3302971

8 reports for AKTX

T+1T+5T+20T+60

75% Hit rate 3 of 4 directional calls best @ T+20▲ +48.47%Apr 9, 2026

Filters

Reports for AKTX — sortable, filterable
	Type				Now
May 28, 2026 12d ago	Press Release NEUTRAL ★ 4/10	$22.05 $14.99	▼ −32.04%	▼ −31.99%	$15.44 (−29.95%)
May 22, 2026 18d ago	8-K BEARISH ★ 7/10	$17.81 $13.43	▲ +24.59%	▲ +25.68%	$15.44 (+13.28%)
May 21, 2026 19d ago	Press Release BEARISH ★ 6/10	$5.14 $22.05	▼ −328.99%	▼ −327.39%	$15.44 (−200.49%)
May 12, 2026 28d ago	Press Release NEUTRAL ★ 4/10	$3.06 $3.50	▲ +14.38%	▲ +14.30%	$15.44 (+404.74%)
Apr 16, 2026 7w ago	EFFECT BEARISH ★ 7/10	$5.12 $6.00	▼ −17.19%	▼ −16.20%	$15.44 (−201.66%)
Apr 9, 2026 8w ago	Press Release BULLISH ★ 6/10	$3.92 $5.12	▲ +30.61%	▲ +27.43%	$15.44 (+294.01%)
Apr 6, 2026 9w ago	Press Release NEUTRAL ★ 4/10	$3.54 $4.25	▲ +20.00%	▲ +15.87%	$15.44 (+336.30%)
Mar 17, 2026 12w ago	Press Release NEUTRAL ★ 4/10	$6.52 $5.48	▼ −15.95%	▼ −15.24%	$15.44 (+136.89%)

US Market Status

Market Closed — Opens in 3h 38m

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access